XyloCor Therapeutics
Rémi Gloeckler, PhD, has more than 25 years of experience in quality and manufacturing leadership in gene and cellular therapy. He was Transgene’s Vice President of pharmaceutical and industrial operations and then formed Pharmincell in September 2011 where he has consulted for leading gene therapy companies both in Europe and North America.
This person is not in any offices
XyloCor Therapeutics
XyloCor Therapeutics is a development-stage, biotechnology company dedicated to developing first-in-class gene therapies for patients with unmet medical need in cardiovascular disease.